Warnyta Minnaard
20-04-2023
If the practitioner doesn’t know where the primary tumor is located, they cannot offer a targeted treatment plan, and nor can they give the patient an estimate of their life expectancy.
Back to newsMore news
GLOW: working toward more treatment options for glioblastoma
23-05-2023
The outlook for patients with glioblastoma has been unfavorable for years, and treatment options remain limited. That is a reason …
Growth Fund invests 325 million euros in Oncode-PACT to accelerate the development of cancer drugs
14-04-2022
The National Growth Fund invests 325 million euros in the Oncode-PACT plan to accelerate the preclinical development process of cancer …
Dutch House of Representatives votes for action of the Minister for arranging (provisional) reimbursement for whole genome sequencing-based DNA testing for most urgent groups of cancer patients
25-02-2021
On February 25 2021, the Dutch House of Representatives adopted a motion approving reimbursement on a provisional basis of a …
The complete DNA test allows for personalized treatment and so limits the chance of undesirable side effects.
Patient